Impact of Antipseudomonal Antibiotics in Patients with Bronchiectasis
Author Information
Author(s): Hagiwara Akihiko, Shuto Hisayuki, Kudoh Ryohei, Omori Shota, Hiramatsu Kazufumi, Kadota Jun-ichi, Fushimi Kiyohide, Komiya Kosaku
Primary Institution: Oita University Faculty of Medicine
Hypothesis
The study investigates the impact of antipseudomonal antibiotics on in-hospital mortality in patients with bronchiectasis who experienced bacterial pneumonia or exacerbation.
Conclusion
The use of antibiotics covering P. aeruginosa does not improve prognosis in patients with bacterial pneumonia or exacerbation of bronchiectasis.
Supporting Evidence
- 4943 patients with bacterial pneumonia and 1914 patients with exacerbation of bronchiectasis were included in the study.
- The in-hospital mortality rate did not differ significantly between the antipseudomonal and nonantipseudomonal groups.
- Length of hospital stay was longer in the antipseudomonal group for exacerbation of bronchiectasis.
Takeaway
This study found that giving certain antibiotics to patients with lung problems didn't help them get better or live longer.
Methodology
The study used a national inpatient database to analyze patients with bronchiectasis admitted for pneumonia or exacerbation between April 2018 and March 2020.
Potential Biases
Potential bias in diagnosis due to reliance on ICD-10 codes and physician determination of admission-precipitating diagnosis.
Limitations
The study could not confirm whether P. aeruginosa was isolated from respiratory samples due to lack of microbiological data.
Participant Demographics
Patients aged 18 years or older with bronchiectasis, with a higher prevalence among older adults and women.
Statistical Information
P-Value
p=0.053 for pneumonia, p=0.287 for exacerbation
Statistical Significance
p=0.053 for pneumonia, p=0.287 for exacerbation
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website